U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period ...

On May 22, an FDA advisory committee unanimously recommended COVID-19 vaccine manufacturers target the JN.1 variant in their formulations.  The Vaccines and Related Biological Products Advisory ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Despite the fact that vaccines against COVID have already undergone strict safety reviews and that people continue to die ...

The FDA is implementing stricter guidance for the approval of COVID-19 vaccines, according to a paper published in The New England Journal of Medicine.

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

At the outset of the meeting, the FDA's new top vaccine regulator, Vinay Prasad, said he and FDA leaders wanted to "give people a little more time to digest the policy." He said that the FDA is still ...

Over the last several days, the safety and efficacy of messenger RNA, or mRNA, vaccines have come under intense scrutiny. On Tuesday, the U.S. Food and Drug Administration announced plans to limit ...

This week, two new leaders at the US Food and Drug Administration announced plans to limit access to covid vaccines, arguing ...

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

The FDA may limit annual COVID-19 boosters to high-risk groups unless clinical trials prove benefits for healthy adults under ...

The vaccine advisory committee for the Food and Drug Administration met Thursday to discuss potential changes to the formula for COVID-19 vaccines for 2025-2026.